<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964195</url>
  </required_header>
  <id_info>
    <org_study_id>CSY-Rifaximin-HXQ</org_study_id>
    <nct_id>NCT02964195</nct_id>
  </id_info>
  <brief_title>Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding</brief_title>
  <acronym>EoR-GEVB</acronym>
  <official_title>Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second People's Hospital of Lanzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of Rifaximin in the treatment of
      cirrhotic gastroesophageal variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal variceal bleeding is the most common and life-threatening condition in
      patients with portal hypertension, which are susceptibility to bacterial infection. However,
      the prophylaxis use of antibiotics remained uncertain and lack of high level evidences.

      The purpose of the study is to evaluate the efficacy of Rifaximin in the treatment of
      cirrhotic gastroesophageal variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All clinical events</measure>
    <time_frame>8 weeks</time_frame>
    <description>All clinical events were defined as occurrence rebreeding, ascitic fluid infection, hepatorenal syndrome, hepatopulmonary syndrome, portal vein thrombosis, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All clinical events</measure>
    <time_frame>6 months</time_frame>
    <description>All clinical events were defined as occurrence rebreeding, ascitic fluid infection, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum endotoxin,</measure>
    <time_frame>8 weeks, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coagulation function</measure>
    <time_frame>8 weeks, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory factors including IL-6, IL-8, TNF-a, IL-1beta</measure>
    <time_frame>8 weeks, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose breath hydrogen test</measure>
    <time_frame>8 weeks, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of intestinal flora</measure>
    <time_frame>8 weeks, and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Esophageal and Gastric Varices</condition>
  <condition>Gastrointestinal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Rifaximin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 400 mg bid for 2 month,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine endoscopic treatment without prophylactic use of antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>ALFA WASSERMANN S.p.A.</description>
    <arm_group_label>Rifaximin Group</arm_group_label>
    <other_name>XIFAXAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 y.o. ≤age≤75 y.o.;

          -  Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include
             esophageal varices ligation, endoscopic injection sclerosis and gastric
             N-butyl-cyanoacrylate injection).

        Exclusion Criteria:

          -  age &lt;18 y.o. or age &gt; 75 y.o.;

          -  Never had the variceal bleeding episode before;

          -  Do not have endoscopic treatment;

          -  combined with other malignant tumor (not exclude patients with hepatocellular
             carcinoma who don't not need treatment at the moment);

          -  Known infection after endoscopic treatment (Fever, microbial cultures positive, et
             al.)

          -  Massive ascites or combined with other high risk factor that require prophylaxis use
             of antibiotics.

          -  Acute variceal bleeding within 5 days.

          -  Use of other antibiotics in the past 2 weeks;

          -  Refuse to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao CHEN, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital, Fudan University, Shanghai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoquan HUANG, M.D.</last_name>
    <phone>18801733835</phone>
    <email>huangxiaoquan1010@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyao CHEN, M.D.</last_name>
    <phone>13601767310</phone>
    <email>chen.shiyao@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoquan HUANG, M.D.</last_name>
      <phone>+86-18801733835</phone>
      <email>huangxiaoquan1010@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Shiyao Chen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.</citation>
    <PMID>20335583</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. Erratum in: Hepatology. 2007 Dec;46(6):2052.</citation>
    <PMID>17879356</PMID>
  </reference>
  <reference>
    <citation>Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, Parodi A, Usai-Satta P, Vernia P, Anania C, Astegiano M, Barbara G, Benini L, Bonazzi P, Capurso G, Certo M, Colecchia A, Cuoco L, Di Sario A, Festi D, Lauritano C, Miceli E, Nardone G, Perri F, Portincasa P, Risicato R, Sorge M, Tursi A; 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009 Mar 30;29 Suppl 1:1-49. doi: 10.1111/j.1365-2036.2009.03951.x. Erratum in: Aliment Pharmacol Ther. 2010 Jan;31(1):166. Satta PU [corrected to Usai-Satta P].</citation>
    <PMID>19344474</PMID>
  </reference>
  <reference>
    <citation>Hwang JH, Shergill AK, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley KQ, Fonkalsrud L, Jue T, Khashab MA, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD; American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc. 2014 Aug;80(2):221-7. doi: 10.1016/j.gie.2013.07.023. Review.</citation>
    <PMID>25034836</PMID>
  </reference>
  <reference>
    <citation>Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013 Mar;28(3):450-5. doi: 10.1111/jgh.12070.</citation>
    <PMID>23216382</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

